Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: The combination of lenalidomide–dexamethasone is active in multiple myeloma (MM). Preclinical data showed that the Akt inhibitor, perifosine, sensitized MM cells to lenalidomide and dexamethasone, providing the rationale for this Phase I, multicentre, single‐arm study to assess the safety and determine the maximum‐tolerated dose (MTD) of perifosine–lenalidomide–dexamethasone in relapsed and relapsed/refractory MM. Patients received escalating doses of perifosine 50–100 mg daily and lenalidomide 15–25 mg once daily on days 1–21 of each 28‐d cycle, plus dexamethasone 20–40 mg weekly thereafter, as indicated. Thirty‐two patients were enrolled across four dose cohorts. MTD was not reached, with 31 patients evaluable for safety/tolerability. The most common all‐causality grade 1‐2 adverse events were fatigue (48%) and diarrhoea (45%), and grade 3–4 neutropenia (26%), hypophosphataemia (23%), thrombocytopenia (16%), and leucopenia (13%). Among 30 evaluable patients, 73% (95% confidence interval, 57·5–89·2%) achieved a minimal response or better, including 50% with a partial response or better. Median progression‐free survival was 10·8 months and median overall survival 30·6 months. Response was associated with phospho‐Akt in pharmacodynamic studies. Perifosine–lenalidomide–dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 4×
“…into our study, more comparable to the patient population enrolled into MM-009 and MM-010 studies, indicated a PR or better rate of 70%, and PFS was 27·7 months, which appears improved when compared to historical data with lenalidomide–dexamethasone (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundResultInfluentialLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 1×
“There is a rationale for inhibiting the Akt signalling pathway in patients with MM, as it promotes cell survival and proliferation, and mediates MM cell resistance to conventional therapeutics (Hideshima et al, 2001, 2004).”
BackgroundSelf-citation
Cited by
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citationSignaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
“Perifosine-lenalidomide-dexamethasone was well tolerated [93].”
Self-citation
Metadata
- Authors
- Jakubowiak, A. J., Richardson, P. G., Zimmerman, T., Alsina, M., Kaufman, J. L., Kandarpa, M., Kraftson, S., Ross, C. W., Harvey, C., Hideshima, T., Sportelli, P., Poradosu, E., Gardner, L., Giusti, K., & Anderson, K. C.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2012-05-29
- Volume
- 158
- Issue
- 4
- Pages
- 472-480
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2033585196
- Cited by
- 62
- References
- 5
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. https://app.cochat.ai/papers/10.1111/j.1365-2141.2012.09173.x
- The paper
- Jakubowiak, A. J., Richardson, P. G., Zimmerman, T., Alsina, M., Kaufman, J. L., Kandarpa, M., Kraftson, S., Ross, C. W., Harvey, C., Hideshima, T., Sportelli, P., Poradosu, E., Gardner, L., Giusti, K., & Anderson, K. C. (2012). Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2012.09173.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.